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ABSTRACT
Non-specific quantitation of [14C]sucrose in blood and brain has been routinely used as a
quantitative measure of the in vivo blood-brain barrier (BBB) integrity. However, the reported
apparent brain uptake clearance (Kin) of the marker varies widely (~100 fold). We investigated
the accuracy of the use of the marker in comparison with a stable isotope of sucrose
([13C]sucrose) measured by a specific LC-MS/MS method. Rats received single doses of each
marker, and the Kin values were determined. Surprisingly, the Kin value of [13C]sucrose was 6-7
fold lower than that of [14C]sucrose. Chromatographic fractionation after in vivo administration
of [14C]sucrose indicated that the majority of the brain content of radioactivity belonged to
compounds other than the intact [14C]sucrose. However, mechanistic studies failed to reveal any
substantial metabolism of the marker. The water: octanol partition coefficient of [14C]sucrose
was > 2 fold higher than that of [13C]sucrose, indicating presence of lipid-soluble impurities in
the [14C]sucrose solution. Our data indicate that [14C]sucrose overestimates the true BBB
permeability to sucrose. We suggest that specific quantitation of the stable isotope (13C) of
sucrose is a more accurate alternative to the current widespread use of the radioactive sucrose as
a BBB marker.
Keywords: blood-brain barrier permeability, [14C]sucrose, [13C]sucrose, apparent brain uptake
clearance
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Introduction
One of the essential features of the blood-brain barrier (BBB) is the presence of complex
intercellular tight junctions between adjacent endothelial cells,1 which results in a very high
transendothelial electrical resistance, estimated at ~1,800 Ω cm2,2 and severely restricts
paracellular passage of polar compounds when compared to vascular beds in other organs.3
Impairment of the BBB is recognized as either a pathophysiologic consequence or a cause of
multiple disease states affecting the CNS, including traumatic brain injury, ischemic stroke, brain
tumors,

and

neuroinflammatory,

infectious,

or

neurodegenerative

brain

disorders.4-8

Measurement of passive BBB permeability is therefore one of the most frequently used
parameters in experimental and clinical studies.
Diverse markers ranging from vital dyes, such as Evans Blue,9 and sugars, like sucrose
and inulin,10 to proteins, such as radiolabeled albumin10,11 and horseradish peroxidase,12 have
been used in the BBB field in preclinical studies to determine the integrity of the barrier. For the
quantification of subtle changes in paracellular permeability, no single ideal marker has emerged
to date.13 For example, as a hydrophilic small drug molecule, atenolol has been occasionally used
to represent putative paracellular transport.14-16 However, while atenolol is 99% charged at
physiological pH, transcellular passage of the neutral form may account for a fraction of brain
uptake measured in vivo.17 In practical terms, a permeability marker should not have significant
pharmacological effects, as it could alter physiological parameters. While not a drug itself, the
disaccharide sucrose may be considered the most widely accepted standard for the precise
measurement of paracellular BBB permeability.18-22 This is because sucrose is uncharged, not
subject to protein binding, metabolically stable after parenteral administration, falling into the
molecular weight range of most small molecule drugs, and, to our knowledge, lacking
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measurable membrane transport by active or facilitative mechanisms in vertebrates. With respect
to in vivo studies, a recent review13 on BBB markers rated radiolabeled sucrose as the only small
molecular weight agent providing quantitatively accurate data. However, at least one earlier
literature report23 indicated that radiolabeled sucrose, especially when used in typical fashion
with counting of just the whole radioactivity in blood and tissue samples (i.e. without
chromatographic separation), may give spurious data due to presence of minor lipophilic
contaminants.
To potentially replace radiolabeled tracers and circumvent the non-specificity of total
radioactivity measurement associated with the use of [14C]sucrose, we recently introduced a
highly specific and sensitive non-radioactive technique for measurement of BBB permeability,
based on LC-MS/MS detection of [13C]sucrose.24 In the current study, we conducted a rigorous
side-by side comparison of the two isotopically labeled sucrose analogs after intravenous bolus
injection in rats.

Materials and Methods
Chemicals and Reagents
We purchased [UL-13C12]sucrose (all the carbons in both glucose and fructose molecules
are labeled with
13

13

C isotope; denoted [13C]sucrose) and the internal standard, which was [UL-

C6fru]sucrose (all the carbons in the fructose molecule are labeled with

13

C isotope), from

Omicron Biochemicals (South Bend, IN, USA). [14C]Sucrose, Solvable, and Hionic-Fluor
solution were purchased from PerkinElmer (Boston, Massachusetts, USA). Specific activity of
the [14C]sucrose stock solution was 400-700 mCi/mmol. LC-MS grade water (J.T. Baker) was
purchased from Avantor Performance Materials, Inc. (Center Valley, PA, USA). 1-Octanol was
purchased from Alfa Aesar (Ward Hill, MA, USA). Analytical grade ammonium hydroxide and
4

LC-MS grade acetonitrile (ACN) were purchased from Fisher Scientific (Fair Lawn, NJ, USA).
For anesthesia, ketamine and xylazine solutions were purchased from Lloyd Laboratories
(Shenandoah, IA, USA). Heparin solution was purchased from APP Pharmaceuticals
(Schaumburg, IL, USA). All other chemicals were analytical grade and obtained from
commercial sources.
Animals
Adult, male Sprague-Dawley rats were purchased from Charles River laboratory
(Wilmington, MA) and acclimated in single, ventilated cages with 12-h dark-light cycles in a
temperature- and humidity-controlled room with free access to the food and water. The average
weight of animals was in the range of 379 – 415 g, and the CV of body weight in each group was
< 5%.
All the animal procedures used in this study were approved by Texas Tech University
Health Sciences Center’s Institutional Animal Care and Use Committee and were consistent with
the guidelines set by the Guide for the Care and Use of Laboratory Animals (National Research
Council, 2011).
In Vivo BBB Permeability to [14C] and [13C]Sucrose
Rats were anesthetized with ketamine: xylazine, and catheters were placed in their penile
vein and femoral artery for drug injection and serial blood sample collection, respectively. For
[14C]sucrose experiments, a single dose of 3 µCi (~ 5 µg/kg) was administered to different
groups of animals, which were then euthanized 30, 60, or 240 min after the injection (n =
3/group). Serial blood samples were collected at different time points before euthanasia. At the
end of sampling, a catheter was placed in the left ventricle and the whole body was perfused with
ice-cold saline at a rate of 25 mL/min for 5 min, and the brain was collected. One hemisphere of
5

the brain was cut into small pieces, and 0.2-0.3 g of the brain tissue was added to 2 mL of
Solvable to digest the tissue. Additionally, 20 µL of blood and plasma samples were added to 2
mL of Solvable. After 24 h at room temperature, 100 µL of hydrogen peroxide was added to
each sample to remove any possible color quenching, and samples were subjected to liquid
scintillation counting after adding 12 mL scintillation fluid.
For [13C]sucrose, different groups of rats were euthanized at 15, 30, 60, 90, 120, or 240
min after injection of [13C]sucrose at a dose of 10 mg/kg (n = 3/group). The purpose of the
additional time points used for [13C]sucrose (15, 90, and 120 min), compared with the
[14C]sucrose experiments, was to further characterize the kinetic profile of this newly developed
marker, which showed a BBB permeability profile different from that of [14C]sucrose. Serial
blood samples and terminal brain were collected as described above for [14C]sucrose. Before
analysis, plasma samples were diluted 100 times with water, and brain was homogenized in icecold water at a ratio of 1:9 to obtain brain homogenate. The brain homogenate and diluted
plasma samples were analyzed by the LC-MS/MS method as described below.
Fractionation of Plasma and Brain [14C]Sucrose after In Vivo Administration
After an overnight fast, rats (n = 3) were anesthetized with a ketamine: xylazine mixture
(80:8 mg/kg) via intramuscular injection, and [14C]sucrose was injected at a dose of 100
µCi/animal (~ 170 µg/kg) via penile vein. During anesthesia, the body temperature of rats was
maintained at 37ᴼC. One h after the sucrose injection, a blood sample was collected from a
femoral artery catheter and plasma was separated. Additionally, a catheter was placed in the left
ventricle of the heart, and whole body perfusion was conducted with ice-cold saline at a rate of
25 mL/min for 5 min. Subsequently, the brain was collected and snap-frozen in cold (-80ᴼC) isopentane. The whole brain was homogenized in ice-cold water (1:4) containing 0.03% sodium
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azide. After centrifugation, 2 mL of the supernatant was condensed to ~200 µL under a nitrogen
stream, followed by addition of 1800 µL of acetonitrile and water mixture (80:20), vortexed,
centrifuged at 20000 g for 10 min, and the supernatant was collected. The supernatant was
divided into two parts; one part was used for HPLC fractionation and radioactivity measurements
of the individual fractions, whereas the other part was used to measure the total, unfractionated
radioactivity in the sample.
For fractionation, the supernatant was injected onto an HPLC column (Unison UKAmino; 150 mm х 2 mm, 3 µm; Imtakt, Portland, OR, USA), using an injection volume of 50 µL
at a time. With a mobile phase of water: acetonitrile (20:80, v/v), run at a flow rate of 0.4
mL/min, sucrose retention time was 4.25 min. Column eluent was collected every 15 sec for 15
min. At the end of all 50 µL injections, the collected fractions at each time point were pooled and
subjected to liquid scintillation counting along with the other portion of the supernatant. To rule
out degradation of [14C]sucrose during sample preparation, blank brain homogenates, obtained
from drug-free rats, were subjected to the same sample preparation process after spiking with
[14C]sucrose concentrations as observed in the in vivo study.
Plasma samples (10 µL) were mixed with 90 µL of acetonitrile: water (80:20), vortexed,
and centrifuged. Similar to the brain samples, the supernatant was divided into two parts (40 µL
each) and subjected to HPLC fractionation or direct measurement of total radioactivity. Similar
to the brain and plasma samples, radioactivity in aliquots of the dosing solution for each animal
was measured directly, and in individual fractions after HPLC fractionation.
In Vitro Stability of [13C]Sucrose in Liver and Brain Homogenates and Blood
Fresh, heparinized blood, collected from rats, and water (control) samples were spiked
with [13C]sucrose to achieve a concentration of 10 ng/mL (n = 3). Fresh drug-free liver and brain
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samples were homogenized (1:9) in citrate-phosphate buffer (100 mM), pH 6.5. Tissue
homogenates and citrate-phosphate buffer (Control) were spiked with [13C]sucrose to achieve a
final concentration of 10 ng/mL. The spiked samples were kept in a shaking water bath at 37ᴼC
for 3 h, and serial samples (20 µL each) were collected and processed for LC-MS/MS analysis.
In Vitro Stability of [13C]Sucrose in Brain Cell Culture
Brain co-cultures consisted of a mixture of mouse primary astrocytes, glial cells, and
neurons after first passage, where cells were 50% confluent. Neurons were 10 days and
astrocytes and glial cells were 17 days old. Total numbers of cells per well were 30,000-40,000
for astrocytes and neurons and 5,000-10,000 for microglial cells. Three different concentrations
of [13C]sucrose (2, 4, and 10 ng/mL) were added to different wells in a 12-well plate, containing
either cells or the culture medium alone (n = 3). The plates were then incubated for 24 h in a
CO2 incubator, and serial samples (20 µL) were collected at different time points (0, 2, 12, and
24 h) and subjected to LC-MS/MS analysis.
In Vitro Stability of [14C]Sucrose in Brain Homogenates
Fresh drug-free brain was homogenized (1:9) in citrate-phosphate buffer (10 mM), pH
6.5, and the resulting brain homogenates were spiked with 2500 dpm/mL (0.7 ng/mL) of
[14C]sucrose. This concentration was selected to be close to the brain concentrations observed
after in vivo administration of 100 µCi of [14C]sucrose in the above fractionation studies. The
spiked homogenates were placed in a shaking water bath at 37ᴼC, and samples were taken at zero
(baseline) and 3 h, and subjected to the same procedure described above for fractionation studies
(i.e., addition of 0.03% sodium azide, centrifugation, 10-fold concentration of the supernatant,
and precipitation of proteins with acetonitrile: water). Similarly, the final supernatant was then
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subjected to both HPLC fractionation, followed by radioactivity measurements of the individual
fractions, in addition to counting of the total, unfractionated radioactivity.
Partition Coefficients of [14C] and [13C]Sucrose
Partition coefficients [14C] and [13C]sucrose between 1-octanol and water were
determined according to the established methods. Water is very slightly soluble in 1-octanol
(1.64 mol/l). Therefore, to reduce any errors during partitioning experiments, equal volumes of
1-octanol and water were mixed together and kept overnight with continuous stirring at room
temperature to pre-saturate 1-octanol with water. The water-saturated 1-octanol was used for the
following studies.
[13C] (100 µg/mL) or [14C] (146000 dpm/mL or ~ 40 ng/mL) sucrose solutions (5 mL)
were made in water and added to an equal volume of pre-saturated 1-octanol in a separating
funnel. Subsequently, the contents of the funnel were mixed for 30 min in a rotary machine, and
samples (500 µL) were taken from both the water and 1-octanol media for analysis. Additionally,
the water part was separated and underwent a second and third partitioning by the addition of
equal volumes of fresh 1-octanol, followed by shaking and sampling as described above. For
[13C]sucrose measurements, undiluted 1-octanol and 100 fold diluted water samples were
analyzed by LC-MS/MS. For [14C]sucrose

measurements, samples were added to the

scintillation fluid and subjected to scintillation counter.
In addition to determination of the partition coefficient of the [14C]sucrose stock solution
used in the animal studies, partition coefficient of a second stock of [14C]sucrose was also
determined to investigate the potential differences between different lots of the marker.
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LC-MS/MS Analysis of [13C]Sucrose
The LC-MS/MS method is described in a recent publication.24 In brief, samples (20 µL),
after proper dilution, were subjected to protein precipitation by the addition of 180 µL of
acetonitrile: water (80:20), which contained IS. Chromatographic separation was then performed
using an Acquity BEH amide column (50 mm х 3 mm, 1.7 µm) and an isocratic mobile phase of
acetonitrile: water: ammonium hydroxide (72:28:0.1, v/v), run a flow rate 0.2 mL/min. Column
temperature was maintained at 45oC. The retention time of sucrose was ~2.5 min. The MRM was
monitored in negative mode, and the transitions for [13C]sucrose and IS were 353à92 m/z and
347à89 m/z, respectively.
As reported before,24 the recovery of [13C]sucrose from the brain homogenates at
concentrations of 10 (94.0%) and 100 (100%) ng/mL was almost quantitative. However,
additional recovery experiments at a brain homogenate concentration of 3 ng/mL (n = 5) were
conducted in the current study to verify the recovery of the marker at concentrations observed in
this study. Similar to the previous method,24 the recovery was determined by comparison of peak
areas of brain homogenates and aqueous solutions spiked with [13C]sucrose and subjected to an
identical sample preparation method. In agreement with the previous report,24 the recovery
(mean ± SD) at a brain homogenate concentration of 3 ng/mL was 102 ± 4%.
Liquid Scintillation Counting
All radioactive samples (brain, plasma, HPLC fractions) were measured in a Beckman
LS6500 liquid scintillation counter with appropriate window settings for 14C. Quench monitoring
(H-number) and automatic quench correction was applied to convert counts per minute (cpm)
into disintegrations per minute per gram tissue (dpm/g) or dpm/mL for brain and plasma
samples, respectively.
10

Pharmacokinetic Analysis
To determine the BBB permeability to both markers in naïve animals, apparent brain
uptake clearance (Kin) values were estimated for individual time groups using the following
equation:25
!

𝐾!" =

!!"!"#$

(1)

!!!

!"#$
!"#!"#$%#

!!"#$
!!!!"#$
where 𝐶!"
and 𝐴𝑈𝐶!"#$%#
are the amount of the marker in the terminal brain sample (in units of

mass/g of brain) corrected for the marker presence in brain plasma and the area under the plasma
concentration-time curve (AUC) from time zero to the last sampling time, respectively. The
!!!

!"#$
𝐴𝑈𝐶!"#$%#
was estimated by the log-linear trapezoidal rule. Additionally, the Kin values were

also estimated from the Patlak plot,26 which is defined by the following equation:
!

!

!!!

!

!"#$
!"#$
!"#$
𝐶!"!"#$ 𝐶!"#$%#
= 𝐾!" × 𝐴𝑈𝐶!"#$%#
𝐶!"#$%#
+ (𝑉! +𝑉! )

(2)

!!"#$
where 𝐶!"#$%#
is the terminal plasma concentration of the marker and Vp and V0 are the volume

of the plasma space (in the absence of brain vascular washout) and an additional hypothetical
volume outside the brain parenchyma in which the marker may be rapidly distributed.
To allow comparison of data between the [13C] and [14C]sucrose, the mass of the markers
in the blood and brain were corrected for the injected dose and expressed as percentage of
injected dose (%ID).
Statistical Analysis
Statistical analysis of data was performed using Prism software (GraphPad Software,
LaJolla, CA). Data with three or more groups were analyzed by one-way ANOVA, followed by
Tukey’s multiple comparisons. Two-way ANOVA, followed by Bonferroni multiple
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!!"#$
comparisons, was used for the comparison of AUC, 𝐶!"
, and Kin values of [13C] and

[14C]sucrose at 30, 60, and 240 min. For in vitro stability studies, the relationships between the
concentration of the marker and time were analyzed using linear regression analysis. In all cases,
a p value < 0.05 was considered significant. Data are presented as mean ± SD or individual
values.

Results
Plasma Kinetics and Brain Disposition Profiles of [13C] and [14C]Sucrose
The plasma concentration-time profiles of [13C] and [14C]sucrose in different groups of
animals, which were euthanized at different time points (15-240 min), are presented in Fig. 1.
Both markers showed similar profiles with an apparent multiexponential decline in their plasma
concentrations. Additionally, the respective area under the plasma concentration-time curve from
!!!

!

!"#$
time zero to the last sampling time (𝐴𝑈𝐶!"#$%#
), terminal brain concentrations 𝐶!"!"#$ , and

apparent brain uptake clearance (Kin) values are presented in Table 1. As expected, the
!!!

!"#$
𝐴𝑈𝐶!"#$%#
values generally increased with an increase in the sampling time for both markers (p

< 0.01, Table 1). The plasma concentration-time course (Fig. 1b) and AUC values (Table 1) of
[13C] and [14C]sucrose for the 30 min groups were very similar and not significantly different
from each other. Although there was a trend towards higher plasma concentrations (Fig. 1c and
Fig. 1f) and AUC values (Table 1) of [14C]sucrose for the 60 min and 240 min groups, the
differences between the AUC values of the two markers were not statistically significant (Table
1).
In contrast to a significant time-dependent increase in the AUC of both markers (Table
1), the terminal brain concentrations of both [13C] and [14C]sucrose remained relatively
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unchanged (P > 0.05) during the 15-240 min sampling period for [13C]sucrose and the 30-240
!!!

!"#$
min sampling period for [14C]sucrose (Table 1). Additionally, despite similar 𝐴𝑈𝐶!"#$%!
values

for [13C] and [14C]sucrose, the brain concentrations of [14C]sucrose were, on average, 7-10 fold
higher than those of [13C]sucrose at the same time intervals (Table 1). In contrast to the
relatively constant brain concentrations, there was a progressive decline in the Kin values with an
increase in the sampling time for both [13C] (p < 0.0001) and [14C] (p < 0.01) sucrose (Table 1).
Of particular note is the finding that the Kin values for [14C]sucrose were, on average, 6.3 (30 min
group), 6.4 (60 min group), or 7.6 (240 min group) fold higher than those for [13C]sucrose at the
corresponding sampling time (p < 0.0001, Table 1). Whereas the Kin values ranged from 0.182 to
0.382 µL/(min.g) for [14C]sucrose, the values for [13C]sucrose ranged from 0.0241 to 0.0801
µL/(min.g) (Table 1).
The Patlak plots for [13C] (Figs. 2a and 2b) and [14C] (Figs. 2c and 2d) sucrose are
depicted in Fig. 2. These plots were constructed using individual animal data for all the time
points (Figs. 2a and 2c) or after exclusion of the 240-min groups (Figs. 2b and 2d). As
demonstrated, exclusion or inclusion of the 240-min group did not substantially affect the
intercepts or slopes of the plots for either [13C] or [14C]sucrose (Fig. 2). The Kin values estimated
from the slopes of the Patlak plots were 0.0229 and 0.173 µL/(min.g) for [13C] (Fig. 2a) and
[14C] (Fig. 2c) sucrose, respectively, indicating a 7.6 fold higher Kin for [14C]sucrose when
compared with the corresponding value for [13C]sucrose. Similarly, the intercept of the line,
which is an indication of a residual volume, was 4.6 fold higher for [14C]sucrose (11.7 µL/g) than
that for [13C]sucrose (2.54 µL/g) (Fig. 2).
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Fractionation of Brain and Plasma Samples after In vivo Administration of [14C]Sucrose
Figure 3 depicts the chromatograms of three individual brain samples (Figs. 3a-3c),
which were collected 1 h after the in vivo administration of [14C]sucrose, along with the
chromatograms of their respective dosing solutions. Additionally depicted in the figure are the
chromatograms of a blank brain homogenate spiked in vitro with [14C]sucrose (Fig. 3d) and a
representative terminal plasma sample collected 1 h after the in vivo administration of
[14C]sucrose (Fig. 3e). As demonstrated in Fig. 3, whereas the dosing solutions (Figs. 3a-c), the
in vitro spiked brain homogenate (Fig. 3d), and the in vivo plasma sample (Fig. 3e) showed a
single peak related to sucrose at ~4.5 min, the chromatograms of the in vivo brain samples
contained several prominent peaks, in addition to the peak expected at the sucrose retention time
(Figs. 3a-3c). In fact, most of the total peak areas in the chromatograms of in vivo brain samples
could be attributed to the retention times other than that for the sucrose peak (Figs. 3a-3c). We
also measured the total radioactivities of the brain samples in the unfractionated samples to
determine the recovery of the radioactivity from the fractionation procedure. The extent of
recovery for the three samples was 95.0 ± 7.5%, indicating the chromatograms represent an
almost complete recovery of the radioactivity in the brain samples.
Stability of [13C]Sucrose in Biological Samples
To determine the possibility of in vivo metabolism of [13C]sucrose, the stability of the
marker in various biological media was tested in vitro at 37oC. To avoid saturation of
metabolism, the concentrations of [13C]sucrose were selected to be much lower than the in vivo
concentrations achieved after intravenous injection of [13C]sucrose (10 ng/mL ≈ 0.00025 %ID
per mL; 4 ng/mL ≈ 0.0001 %ID/mL, and 2 ng/mL ≈ 0.00005 %ID/mL). Figure 4 demonstrates
the concentration-time courses of [13C]sucrose in brain homogenate (Fig. 4a), brain cell co-
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culture (Fig. 4b), liver homogenate (Fig. 4c), and blood (Fig. 4d). There were no significant
changes in the concentrations of the marker in any of the biological samples tested as the slopes
of the regression lines for all the biological samples were not significantly (p > 0.05) different
from zero (Fig. 4).
Also shown in Fig. 4 are the chromatograms of brain homogenates before (time zero) and
3 h after incubation of a low concentration (2500 dpm or 0.7 ng per mL) of [14C]sucrose at
37oC, followed by HPLC fractionation of the samples (Fig. 4e). As demonstrated, both
chromatograms showed a single major peak at the expected retention time of sucrose (4.25 min),
which were virtually superimposable for the zero and 3 h samples, indicating no noticeable
metabolism of [14C]sucrose during the incubation period. Finally, the recovery of [14C]sucrose
from the HPLC fractions, relative to the unfractionated samples, was quantitative, indicating
complete recovery of the radioactivity form the HPLC column during the 15 min run.
Octanol: Water Partition Coefficient of [13C] and [14C]Sucrose
The octanol: water partition coefficient (Kp) values of [13C] and [14C]sucrose after three
successive partitioning procedures are presented in Fig. 5. The Kp values of [13C]sucrose after the
first (2.75 x 10-4 ± 0.07 x 10-4), second (2.66 x 10-4 ± 0.21 x 10-4), and third (2.63 x 10-4 ± 0.29 x
10-4) experiments were almost identical (p > 0.05) (Fig. 5a). However, the Kp values of
[14C]sucrose after the second (4.67 x 10-4 ± 0.41 x 10-4) and third (4.32 x 10-4 ± 0.26 x 10-4)
experiments were significantly (p < 0.01 and < 0.001, respectively) lower than that after the first
experiment (5.74 x 10-4 ± 0.40 x 10-4) (Fig. 5b). Furthermore, the Kp value of [14C]sucrose (Fig.
5b) after the first experiment was more than two-fold higher than the corresponding value for
[13C]sucrose (Fig. 5a). Even after the third partitioning experiment, the Kp value of [14C]sucrose
(Fig. 5b) remained 60% higher than the corresponding value for [13C]sucrose (Fig. 5a). The
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partition coefficient values for a second lot of [14C]sucrose (Fig. 5c), which was not used in the
studies reported here, were very similar to those of the lot used in the current studies (Fig. 5b) in
terms of both absolute values and pattern after successive partitioning.

Discussion
The search for ideal markers for the in vivo assessment of BBB integrity has been elusive.
However, radiolabeled small molecules, such as sucrose and inulin, are believed to be one of the
most appropriate groups of markers for the evaluation of the BBB integrity in pathological
conditions.13 In particular, radiolabeled [14C]sucrose has been extensively used for quantitative
determination of BBB integrity in many in vitro,27-30 in situ brain perfusion,31-36 and in vivo11,1822,37-45

studies. This is because sucrose is a water-soluble molecule with no significant

metabolism after parenteral injection, no binding to plasma or tissue proteins, and very low
permeability across the intact BBB. However, the literature values for the in vivo permeability of
intact rat BBB to [14C]sucrose, measured as the Kin value, vary widely, making it difficult to
determine the true permeability of the BBB to the marker.
Two different methods have been used in the literature for the determination of the in
vivo apparent brain influx clearance (Kin) of sucrose.25 The single-brain sample method uses one
group of animals to determine the terminal brain concentration and the plasma AUC of the
marker over a defined sampling time (Equation 1). The multiple-brain sample method is based
on the Patlak plot (Equation 2), which requires similar data obtained from multiple groups of
animals with terminal brain samples taken at multiple times after the marker dosing. In the
current study, we employed both methods for the estimation of Kin using both [14C] and
[13C]sucrose markers (Table 1 and Fig. 2). Our results show that the single-brain sample Kin
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values decline with time for both markers (Table 1), and the values for the longest tested
sampling time (240 min) are close to the corresponding values obtained from the Patlak method
(Fig. 2). The Kin values obtained from the slope of the Patlak plot are theoretically more accurate
as any intercept arising from the residual blood contamination in the brain and/or distribution of
sucrose to a fast-equilibrating space in the brain (represented by V0 in Equation 2)26 does not
contribute to the Kin value.
The estimation of Kin using Equation 1 and Equation 2 are based on the assumption that
brain is a compartment separate from the plasma and other tissues, receiving the marker through
a unidirectional transfer from the plasma.25,26,46 For very low permeability markers, such as
sucrose, assuming unidirectional or bidirectional transfer would essentially yield the same results
if sampling time is relatively short (within minutes to few hours). This is because the main
determinant of the brain concentration is the rate of entry of the marker into the brain from the
plasma, where the concentrations are much higher than those in the brain (for [13C]sucrose: 500
and 100 fold at 15 min and 2 h, respectively; Fig. 1 and Table 1). The rate of back transfer of the
marker from the brain to plasma would be negligible during the time when plasma
concentrations are much higher than those in the brain. Using a two-compartment model with
plasma and brain as separate compartments, Ohno et al.20 predicted that the brain concentrations
of sucrose would reach its maximum around 60 min after an intravenous dose of the tracer, with
a very slow rate of decline afterward.20 However, this model did not include the additional, fastequilibrating space in the brain (represented by V0 in Equation 2), which was suggested by Patlak
et al.26 In our studies, we observed relatively constant brain concentrations for both [13C] and
[14C]sucrose during the entire sampling period (15 min to 4 h) (Table 1). Therefore, our data is in
agreement with the presence of the fast-equilibrating space in the brain26 and/or contamination of
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our brain samples with residual blood, which both prominently add to the total brain
concentrations of the markers at the earlier time points, thus overestimating the brain
concentrations and Kin values at those single-brain sample points (Table 1).
Regardless of the experimental design, however, the Kin values obtained for the
radioactive [14C]sucrose were 6.3-7.6 fold higher than those for [13C]sucrose (Table 1 and Fig.
2). This surprising finding prompted us to conduct brain fractionation studies, which revealed
that, indeed, most of the radioactivity in the brain after the in vivo administration of [14C]sucrose
was attributable to compounds other than the intact sucrose molecule (Fig. 3). In fact, if one
could accurately estimate and use the radioactivity related to the sucrose peak only (Figs. 3a-c) in
calculation of Kin values for [14C]sucrose , the 6-7-fold difference in the Kin values between 14Cand [13C]sucrose would likely disappear.
Although it is generally believed that sucrose does not enter cells and is not subject to
significant metabolism after intravenous administration, the possibility of minor metabolism of
the marker in the liver by a very low activity sucrase enzyme has been raised.47 Additionally,
other investigators have shown that α-glucosidase activity, which breaks down starch and
disaccharides to glucose, is also present in brain tissue.48 Therefore, based on the fractionation
studies (Fig. 3), we initially hypothesized that the intact [14C]sucrose entered into the brain is
subsequently metabolized in the brain. However, our in vitro studies with [13C]sucrose in the
brain homogenates (Fig. 4a) and brain cell co-cultures (Fig. 4b) did not support this hypothesis.
Although we tested the in vitro metabolism of [13C]sucrose in brain at concentrations
that were much lower (Figs. 4a and 4b) than those obtained after in vivo administration of the
marker (Table 1), these concentrations were still much higher than the in vivo brain
concentrations of [14C]sucrose (Table 1). Therefore, it might be argued that metabolism of
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sucrose at [13C]sucrose concentrations used in our in vitro studies (Figs. 4a and 4b) is saturated.
Consequently, an additional experiment was conducted to test the metabolism of [14C]sucrose at
very low brain concentrations, similar to those observed after our in vivo experiments (Figs. 3a–
3c). The results of these experiments at low [14C]sucrose concentrations (Fig. 4e) were in
agreement with those at higher concentrations of [13C]sucrose (Fig. 4a), which showed absence
of any noticeable in vitro metabolism of sucrose in the brain homogenate. Furthermore, in vitro
spiking of the brain homogenate and subjecting it to the sample preparation method used in the
fractionation study did not reveal any additional peaks other than the intact [14C]sucrose (Fig.
3d). Therefore, presence of substantial peaks appearing in the brain chromatograms after in vivo
administration of [14C]sucrose (Figs. 3a-c) cannot be attributed to a potentially significant
metabolism of [14C]sucrose in the brain.
Alternatively, [14C]sucrose could be metabolized in the periphery and the metabolites
enter the brain. However, in vitro studies in the liver (Fig. 4c) and blood (Fig. 4d) did not reveal
any substantial peripheral metabolism of the marker. Nevertheless, our studies do not rule out a
very minor peripheral metabolism of sucrose to highly BBB permeable metabolites. Although
the apparent Kin value of [14C]sucrose, traditionally obtained by counting total radioactivity of
brain and plasma samples without fractionation, is susceptible to error by a potential peripheral
metabolism, the specific measurement of [13C]sucrose by LC-MS/MS method is devoid of such
potential problems.
A previous study23 showed that old stocks of [14C]sucrose produce higher Kin values
when compared with new stocks of the marker. Based on the Patlak plots, the Kin values for new,
4-year-old, and 7-year-old stocks of [14C]sucrose showed Kin values across different regions of
the brain in the ranges of 0.072-0.14, 0.31-0.38, and 0.50-0.58 µL/(min.g), respectively. It was
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speculated that these differences were due to presence of impurities in the older stocks of
[14C]sucrose, which could readily cross the BBB. Our stock solution of [14C]sucrose was new
and the Patlak plot of [14C]sucrose data in our studies (Fig. 2c) resulted in a Kin value of 0.173
µL/(min.g), which was close to the values reported by Preston et al.23 for their new stock.
Therefore, we first concentrated on other possibilities, such as the in vivo metabolism of
[14C]sucrose. However, after failing to demonstrate any appreciable metabolism of [14C]sucrose
(Fig. 4), we hypothesized that even a new stock solution of [14C]sucrose might have small
quantities of BBB permeable impurities, which could result in the observed peaks in the brain
chromatograms (Figs. 3a-c) and an overestimation of the true Kin value. Indeed, our successive
water: octanol partitioning experiments, demonstrating higher Kp value for [14C]sucrose,
compared with that of [13C]sucrose, clearly show that the lipid solubility of the two marker
solutions are not similar as expected. These experiments are in agreement with the presence of
lipid soluble impurities in the [14C]sucrose solution, which are partially removed by successive
partitioning (Fig. 5). Collectively, these data suggest that the 6-7 fold higher Kin values observed
in our studies for [14C]sucrose, compared with [13C]sucrose, is due to the presence of BBB
permeable impurities in the [14C]sucrose stock solution combined with the non-specific
radioactive counting of the brain samples. Therefore, the [13C]sucrose Kin values obtained by the
specific LC-MS/MS method of quantitation should represent a more accurate estimation of the
BBB permeability to sucrose.
In addition to the extent of the radioactive impurities, the nature of impurities and their
BBB permeability properties are important factors that could affect the outcome of studies with
[14C]sucrose. For instance, Preston et al.23 showed that whereas the new and 4-year-old stock of
[14C]sucrose showed the same percentage of impurities, the older stock resulted in 3.5 fold
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higher Kin values. Therefore, presence of even a small percentage of a highly BBB permeable
impurity may drastically increase the estimated Kin value of [14C]sucrose using the traditional
nonspecific, total radioactivity counting method. Based on the above considerations, it appears
also plausible that the true Kin values of other BBB permeability markers may be substantially
lower than those reported in the literature, at least when used in form of tracers labeled with
radioisotopes. The polysaccharide inulin may serve as a case in point. It is considered a
hydrophilic marker of passive permeability with an average molecular weight of 5,000 Da, about
15 times the molecular weight of sucrose. The estimated Kin of [3H]inulin ranged between 0.044
and 0.062 µL/(min.g), which was close to half the Kin of [14C]sucrose measured in parallel in the
same study.19 However, that inulin Kin value is 2-3 fold higher compared to the Kin of 0.0229
µL/(min.g) as determined in our present experiments for [13C]sucrose. These data suggest that,
like [14C]sucrose, the previously reported Kin values for [3H]inulin are also an overestimation of
the true BBB to inulin.
Radioactive sucrose in any format (14C or 3H-labeled) is unsuitable for clinical use. In
contrast, nonradioactive sucrose is nontoxic as a nutrient, and it is an ingredient in parenteral
drug formulations (e.g., iron sucrose and some preparations of IVIG). From that perspective,
[13C]sucrose could potentially be used in humans as a marker of BBB permeability. An example
is brain microdialysis sampling, which is applied for metabolic monitoring in neurointensive care
of patients suffering traumatic brain injury or subarachnoid hemorrhage49 and in clinical studies
in glioblastoma patients.50 Given the sensitivity and accuracy of the analytical measurement of
[13C]sucrose by LC-MS/MS, quantification in microdialysate samples after systemic
administration (e.g., intravenous bolus or infusions) could be used to monitor BBB permeability
in humans.
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There are variations in experimental designs in the literature for the in vivo determination
of Kin values. For example, whereas some investigators remove the residual blood form the brain
by in situ perfusion at the terminal sampling time, others use brain vascular markers, such as
radiolabeled albumin, to estimate the contribution of brain blood to the brain concentrations of
the marker. Additionally, as mentioned above, some investigators use the single-brain method
while others use the multiple-brain (Patlak) method. Therefore, the question becomes what
experimental design would likely yield the most accurate estimate of the true Kin value of
sucrose. Based on our findings here, we propose to use the [13C]sucrose marker in at least two
groups of animals with different sampling intervals (such as 1 and 2 h), followed by removal of
the residual blood, as much as possible using the in situ perfusion of the brain, and construction
of the Patlak plot. Alternatively, if only one group of animals is used, we suggest a longer
sampling time (such as 2 h) to reduce the error associated with single-brain sample method at
earlier time points.

Conclusions
In conclusion, our data indicate that the use of [14C]sucrose as a marker of BBB
permeability might result in a substantial overestimation of the true BBB permeability to sucrose.
This is mainly due to the non-specific method of quantitation of the total radioactivity in the
brain, which might contain substantial amounts of radioactive compounds other than the intact
marker. We suggest that the LC-MS/MS quantitation of the stable isotope (13C) of sucrose is a
more accurate alternative to the current widespread use of the radioactive sucrose as a BBB
marker.
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Table 1

FIGURE LEGENDS
Figure 1. Plasma concentration-time courses of [13C] (a-f) and [14C] (b, c, and f) sucrose in rats.
Different groups of animals (n = 3/group) received a single intravenous dose of [13C]sucrose (10
mg/kg) or [14C]sucrose (3 µCi). Serial blood samples were taken over 15 (a), 30 (b), 60 (c), 90
(d), 120 (e), or 240 (e) min for [13C]sucrose or over 30 (b), 60 (c), or 240 (f) min for 14C-sucrose.
Symbols and bars represent mean and SD values, respectively.
Figure 2. Patlak plots of [13C] (a and b) and [14C] (c and d) sucrose in rats, including (a and c)
and excluding (b and d) the 240 min group data. Different groups of animals (n = 3/group)
received a single intravenous dose of [13C]sucrose (10 mg/kg) or [14C]sucrose (3 µCi). Serial
blood samples were taken over 15, 30, 60, 90, 120, or 240 min for [13C]sucrose or over 30, 60, or
240 min for [14C]sucrose. Terminal brain samples were also collected after blood removal.
Symbols represent individual animals.
Figure 3. HPLC fractionation of brain samples collected 1 h after the in vivo administration of
[14C]sucrose (a, b, and c), a blank brain homogenate spiked in vitro with [14C]sucrose (d), and a
representative plasma sample collected after the in vivo administration of [14C]sucrose (e). For
comparison, the fractionation of dosing solutions is also shown along with each brain sample (ac). For in vivo experiments, a single intravenous dose (100 µCi) of [14C]sucrose was injected into
the rats (n = 3), and brain (after blood removal) and plasma samples were collected at 1 h after
dosing.
Figure 4. In vitro stability of [13C]sucrose in brain homogenate (a), brain cell co-culture (b), liver
homogenate (c), and blood (d) and that of [14C]sucrose in brain homogenate (e). [13C]Sucrose
was incubated at 37oC for 180 min (brain homogenate, liver homogenate, and blood) or 24 h
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(brain cell co-culture), and serial samples were collected. For comparisons, the time courses of
[13C]sucrose concentrations in the buffer or medium are also included. The brain (a) and liver (c)
homogenate experiments were conducted simultaneously using the same buffer control. The
concentrations of [13C]sucrose were selected to be much lower than the in vivo concentrations
achieved after intravenous injection of [13C]sucrose (10 ng/mL ≈ 0.00025 %ID per mL; 4 ng/mL
≈ 0.0001 %ID/mL, and 2 ng/mL ≈ 0.00005 %ID/mL). Symbols and bars represent mean and SD
values (n = 3), respectively, and the lines represent linear regression analysis of data. For
[14C]sucrose (e), brain homogenate samples were spiked with 2500 dpm or 0.7 ng per mL of the
marker and incubated at 37oC for 3 h. Subsequently, samples were taken at zero (before
incubation) and 3 h and subjected to HPLC fractionation before counting. Also included in Fig.
4e are chromatograms of blank (vehicle) and tracer solutions.
Figure 5. Octanol: water partition coefficient (Kp) of [13C] (a) and [14C] (b) sucrose (n =
5/marker), which were used for in the current in vitro and in vivo studies, and a second lot of
[14C]sucrose (c), which is demonstrated for comparative purposes (n = 3). Aqueous samples
were successively partitioned for 3 times. Symbols and horizontal lines represent individual and
mean values, respectively. **p < 0.01; ***p < 0.001 based on one-way ANOVA, followed by
Tukey’s post-hoc analysis.
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